Chronic Lymphocytic Leukemia

Disease State Hub

Q&As

Expert Q&A

Expert Q&A

Multidisciplinary Management of Cardiovascular Risk in Patients With CLL on BTK Inhibitors

11/04/2025

Daniel Lenihan, MD, FACC, FESC

Daniel Lenihan, MD, FACC, FESC, FIC-OS, a cardio-oncologist and founder of the International Cardio-Oncology Society, discusses cardiovascular risks associated with Bruton's tyrosine kinase inhibitors in...

11/04/2025

Research Summaries

Research Summary

Research Summary

Bexobrutideg Shows Rapid, Durable Responses in Relapsed/Refractory CLL in Updated Phase 1a Trial Data

12/16/2025

Anthony Calabro, MA

Investigators evaluating the novel Bruton's Tyrosine Kinase degrader bexobrutideg (NX-5948) reported updated Phase 1a results demonstrating rapid and durable clinical responses in heavily pretreated...

12/16/2025

CONFERENCE COVERAGE

CONFERENCE COVERAGE

Real-World Outcomes Comparing Venetoclax and BTK Inhibitors Among Patients with Chronic Lymphocytic Leukemia

12/12/2025

Anthony Calabro, MA

A large, real-world comparative analysis evaluated 1-year clinical and safety outcomes among patients with chronic lymphocytic leukemia receiving venetoclax-based versus Bruton's tyrosine kinase...

12/12/2025

Research summary

Research summary

Can an eHealth Platform Improve Quality of Life for Patients with Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes?

11/18/2025

Anthony Calabro, MA

A randomized controlled trial evaluated the MyPal eHealth platform’s impact on quality of life among patients with chronic lymphocytic leukemia and myelodysplastic syndromes, revealing significant...

11/18/2025

Research Summary

Research Summary

Real-World Analysis Finds Higher Discontinuation and Hospitalization Rates With BTK Inhibitors vs Fixed-Duration Venetoclax in Older Adults With CLL

09/10/2025

Kate Young

Adults 66 years and older with CLL who began treatment with a Bruton’s tyrosine kinase inhibitor were more likely to discontinue early, require subsequent therapy, and experience hospitalization compared...

09/10/2025

Research Summary

woman taking pills with a glass of water

Research Summary

Ibrutinib–Venetoclax Outperforms Ibrutinib Alone and FCR in CLL: Long-Term Results from Phase 3 FLAIR Trial

07/08/2025

Anthony Calabro, MA

A phase 3 trial confirms that combining ibrutinib with venetoclax yields superior measurable residual disease clearance, progression-free survival, and overall survival in patients with chronic lymphocytic...

07/08/2025

January 2026

Current Issue

January 2026